Skip to content

Efficacy of Cochlear Implantation in Pediatric Patients with Congenital Single-Sided Deafness: A Prospective Multicenter Study

Efficacy of Cochlear Implantation in Pediatric Patients with Congenital Single-Sided Deafness: A Prospective Multicenter Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0010964
Enrollment
20
Registered
2025-08-29
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Pediatric patients under 18 years of age with congenital unilateral sensorineural hearing loss. 2.Based on pure-tone audiometry thresholds calculated using the six-frequency method at 500, 1000, 2000, and 4000 Hz: -Worse ear: PTA = 70 dB HL and aided speech discrimination score (SDS) = 50% at 60 dB SPL. -Better ear: PTA = 40 dB HL and SDS = 80% at 60 dB SPL. 3.If pure-tone audiometry is not feasible, auditory brainstem response (ABR) will be used: -Worse ear threshold = 90 dB nHL for patients under 1 year of age. -Worse ear threshold = 70 dB nHL for patients 1 year of age or older. 4.Insufficient hearing improvement with hearing aid use in the worse ear. 5.No contraindications to surgery or general anesthesia. 6.Voluntary written informed consent obtained after adequate explanation of the study purpose and procedures. 7.Temporal bone computed tomography (CT) confirming suitability for cochlear implantation. 8.Ability to participate in follow-up assessments for 1 year after study enrollment.

Exclusion criteria

Exclusion criteria: 1.Participants deemed unsuitable for study participation due to mental or physical conditions. 2.Individuals with acquired sensorineural hearing loss (e.g., sudden sensorineural hearing loss). 3.History of medications or systemic conditions that may affect hearing (e.g., ototoxic drugs such as chemotherapy agents). 4.Any other condition deemed inappropriate for study participation by the clinical investigator.

Design outcomes

Primary

MeasureTime frame
Subjective satisfaction was set as the main evaluation metric and compared pre- and postoperatively using several questionnaires (APHAB, SSQ, PEACH). Changes in speech discrimination scores were also analyzed.

Secondary

MeasureTime frame
Improvements in frequency-specific hearing gain (functional gain) assessed by pure-tone audiometry, and in speech performance outcomes.

Countries

Korea, Republic of

Contacts

Public ContactYe Seul Kim

Asan Medical Center

wd11111@naver.com+82-2-3010-3711

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026